Keyword | CPC | PCC | Volume | Score | Length of keyword |
---|---|---|---|---|---|
cancer care ontario pembrolizumab | 1.74 | 0.5 | 2024 | 2 | 33 |
cancer | 0.67 | 0.4 | 4950 | 11 | 6 |
care | 0.41 | 0.6 | 3061 | 88 | 4 |
ontario | 0.6 | 0.3 | 6125 | 20 | 7 |
pembrolizumab | 0.1 | 0.2 | 8885 | 98 | 13 |
Keyword | CPC | PCC | Volume | Score |
---|---|---|---|---|
cancer care ontario pembrolizumab | 0.84 | 0.1 | 5612 | 53 |
pembrolizumab for cancer patients | 0.53 | 0.8 | 8836 | 46 |
pembrolizumab cancer research uk | 1.13 | 0.1 | 2077 | 29 |
breast cancer now pembrolizumab | 0.76 | 0.8 | 3901 | 90 |
pembrolizumab for breast cancer | 1.24 | 0.5 | 5569 | 61 |
pembrolizumab for lung cancer | 0.86 | 1 | 4844 | 47 |
pembrolizumab chemotherapy lung cancer | 0.52 | 0.3 | 2640 | 5 |
pembrolizumab cervical cancer uk | 1.73 | 0.7 | 6794 | 99 |
pembrolizumab lung cancer fda | 0.5 | 0.6 | 4217 | 88 |
pembrolizumab for ovarian cancer | 1.96 | 0.2 | 6208 | 55 |
pembrolizumab for head and neck cancer | 0.3 | 0.8 | 6428 | 42 |
cancer uk pembrolizumab consent | 0.78 | 0.7 | 6884 | 4 |
pembrolizumab breast cancer approval | 0.37 | 0.6 | 4270 | 40 |
pembrolizumab lung cancer fda approval | 1.83 | 0.2 | 6454 | 21 |
pembrolizumab enfortumab bladder cancer | 0.88 | 0.8 | 5619 | 66 |
pembrolizumab ovarian cancer approval | 0.66 | 0.9 | 3625 | 7 |
why pembrolizumab is used for cancer | 1.97 | 0.1 | 3198 | 34 |
pembrolizumab for cervical cancer | 1.14 | 1 | 5146 | 30 |
pembrolizumab breast cancer fda approval | 1.89 | 0.8 | 8918 | 95 |
pembrolizumab product monograph canada | 1.29 | 0.7 | 1198 | 68 |